Analyst firms · B. Riley Securities · CAPR

B. Riley Securities CAPR price target and rating history

Capricor Therapeutics Inc. (CAPR) · Health Care

B. Riley Securities rates Capricor Therapeutics Inc. (CAPR) Buy with a $21 price target, as of its latest action on Sep 14, 2026. It has published 3 rating actions on CAPR since June 2025, including 1 upgrade and 1 downgrade. Across 6 firms with a CAPR price target in the last 12 months, the median target is $23. B. Riley Securities's $21 is 9% below that.

Current rating
Buy
Price target
$21
Median target, all firms
$23
Actions on CAPR
3

B. Riley Securities price target on CAPR

$21$16$102026
B. Riley Securities price target on CAPR, each point a stated target, June 2025 to September 2026.

Every B. Riley Securities rating on CAPR

How other firms rate CAPR

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
B. Riley SecuritiesBuy$21Sep 14, 2026
Piper SandlerOverweight$25Sep 1, 2026
OppenheimerOutperform$54Aug 25, 2026
Cantor FitzgeraldOverweight$28Aug 14, 2026
Maxim GroupHoldJul 30, 2026
H.C. WainwrightNeutralJul 30, 2026
Ladenburg ThalmannNeutralJul 30, 2026
Alliance Global PartnersNeutral$7Jul 28, 2026
Roth CapitalNeutral$7Jul 27, 2026

Questions about B. Riley Securities and CAPR

What is B. Riley Securities's price target for CAPR?
B. Riley Securities's latest stated price target for Capricor Therapeutics Inc. (CAPR) is $21, from its action on Sep 14, 2026.
What is B. Riley Securities's rating on CAPR?
B. Riley Securities rates CAPR Buy, a bullish rating, as of Sep 14, 2026.
When did B. Riley Securities last change its view on CAPR?
On Sep 14, 2026, B. Riley Securities upgrades to Buy from Neutral, price target $21.
How does B. Riley Securities's CAPR target compare with other analysts?
Across 6 firms with a CAPR price target in the last 12 months, the median target is $23. B. Riley Securities's $21 is 9% below that.

More CAPR rating histories

All B. Riley Securities ratingsCAPR news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.